Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?

Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity?

The prolongation of the QT interval is a relatively rare but serious adverse drug reaction. It can lead to torsade de pointes, which is potentially life-threatening. The study’s objectives were: determine the use of QT interval-prolonging drugs in an elderly community-dwelling population a...

Full description

Bibliographic Details
Main Authors:	Vera H. Buss, Kayla Lee, Mark Naunton, Gregory M. Peterson, Sam Kosari
Format:	Article
Language:	English
Published:	MDPI AG 2018-12-01
Series:	Journal of Clinical Medicine
Subjects:	QT interval prolongation torsade de pointes medication review pharmacist intervention
Online Access:	https://www.mdpi.com/2077-0383/7/12/533

Similar Items

Identification of Risk of QT Prolongation by Pharmacists When Conducting Medication Reviews in Residential Aged Care Settings: A Missed Opportunity?
by: Louise Christensen, et al.
Published: (2019-11-01)

Patient safety: prescription of drugs that prolong the QT interval
by: María Jesús Hernández-Arroyo, et al.
Published: (2015-09-01)

A case of hypoglycemiainduced QT prolongation leading to torsade de pointes and a review of pathophysiological mechanisms
by: Faris Hannoodi, et al.
Published: (2017-06-01)

Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study
by: Qasim Khan, et al.
Published: (2017-12-01)

Dose-Dependent Effects of Methadone on QT interval in Patients under Methadone Maintenance Treatment
by: Farzad Gheshlaghi, et al.
Published: (2013-03-01)

A Case of Ciprofloxacin-Induced QT Prolongation and Torsade de Pointes
by: Hedieh Keshavarz-Bahaghighat, et al.
Published: (2017-09-01)

QT Prolongation in Cancer Patients
by: Peter Kim, et al.
Published: (2021-02-01)

Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study
by: Zahid Ali, et al.
Published: (2020-06-01)

Torsades de Pointes associated with QT prolongation after catheter ablation of paroxysmal atrial fibrillation
by: Yae Min Park, et al.
Published: (2017-09-01)

Acquired long QT syndrome and Torsades de Poin
by: Ahmet Seyfeddin Gurbuz, et al.
Published: (2016-09-01)

Prevalence of Prolonged QTC Interval in Patients Taking Psychopharmacs
by: Jovanovic Zoran, et al.
Published: (2018-06-01)

Torsadogenic potential of a novel remyelinating drug clemastine for multiple sclerosis assessed in the rabbit proarrhythmia model
by: Satoshi Kawakami, et al.
Published: (2020-11-01)

CORONAVIRUS DISEASE (COVID-19) TREATMENT ALGORITHMS IN PATIENTS WITH QT INTERVAL PROLONGATION
by: Kalatsei L. V., et al.
Published: (2020-05-01)

Recurrent takotsubo with prolonged QT and torsade de pointes and left ventricular thrombus
by: Alaa Eldin K. Ahmed, et al.
Published: (2017-01-01)

Association between C-reactive protein, corrected QT interval and presence of QT prolongation in hypertensive patients
by: Kai-Ting Chang, et al.
Published: (2014-06-01)

Torsades de pointes after prolonged intravenous amiodarone therapy for atrial fibrillation
by: Irina Nordkin, et al.
Published: (2021-01-01)

Top 20 drug − drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients
by: Biswadeep Das, et al.
Published: (2020-01-01)

Associations of serum and dialysate electrolytes with QT interval and prolongation in incident hemodialysis: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study
by: Esther D. Kim, et al.
Published: (2019-04-01)

Genetic and Molecular Aspects of Drug-Induced QT Interval Prolongation
by: Daniela Baracaldo-Santamaría, et al.
Published: (2021-07-01)

CLINICAL SIGNIFICANCE OF DRUGINDUCED INTERVALS QT AND QTC PROLONGATION
by: N. V. Furman, et al.
Published: (2015-09-01)

Ondansetron induced torsades de pointes
by: Eshan Patel, et al.
Published: (2019-08-01)

A hosszú-QT-szindróma és a torsades de pointes kamrai tachycardia története Historical overview of long-QT syndrome and torsades de pointes ventricular tachycardia
by: Fazekas Tamás, Prof. Dr
Published: (2012-12-01)

CLINICAL SIGNIFICANCE OF DRUGINDUCED INTERVALS QT AND QTC PROLONGATION
by: N. V. Furman, et al.
Published: (2015-09-01)

Multi-Factorial Causes of Torsade De Pointes in a Hospitalised Surgical Patient
by: Prashanth Panduranga, et al.
Published: (2013-02-01)

LONG QT SYNDROME. PART 2
by: Kalatsei L. V., et al.
Published: (2018-11-01)

In vivo analysis of torsadogenic potential of an antipsychotic drug paliperidone using the acute atrioventricular block rabbit as a proarrhythmia model
by: Mihoko Hagiwara, et al.
Published: (2016-09-01)

Long QT syndrome: A therapeutic challenge
by: Shah Maully, et al.
Published: (2008-01-01)

Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes
by: Karthik Gnanapandithan, et al.
Published: (2021-02-01)

Methods of Assessment and Clinical Relevance of QT Dynamics
by: Beata Sredniawa, et al.
Published: (2005-07-01)

QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias: Post-hoc analysis from a large-scale multicenter post-marketing survey in Japan
by: Takao Katoh, MD, et al.
Published: (2013-10-01)

Drug-induced QT interval prolongation in cancer patients
by: Torben K. Becker, et al.
Published: (2011-12-01)

Prognostic value of QT interval prolongation in patients with acute ischemic stroke
by: Iranmanesh F (MD), et al.
Published: (2012-12-01)

Methadone induced torsades de pointes and ventricular fibrillation: A case review
by: Somayeh Khalesi, et al.
Published: (2014-11-01)

Dofetilide induced torsade de pointes: Mechanism, risk factors and management strategies
by: Abhishek Jaiswal, et al.
Published: (2014-11-01)

Editorial: Safety Pharmacology – Risk Assessment QT Interval Prolongation and Beyond
by: Eleonora Grandi, et al.
Published: (2018-06-01)

Postanesthetic torsade de pointes in a patient with unrecognized long QT syndrome -A case report-
by: Jae-Young Lee, et al.
Published: (2011-04-01)

Mexiletine shortens the QT interval in a pedigree of KCNH2 related long QT syndrome
by: Taishi Fujisawa, et al.
Published: (2020-02-01)

Safety Pharmacology - Risk Assessment QT Interval Prolongation and Beyond
Published: (2018)

Q-T interval prolongation in cirrhosis: Relationship and severity
by: Ali Akbar Hajiaghamohammadi, et al.
Published: (2018-05-01)

Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate
by: Li-yu Liang, et al.
Published: (2020-10-01)